Waters Corporation
WAT
$358.25
+0.79%
Waters Corporation is a leading provider of analytical instruments and software, specializing in liquid chromatography, mass spectrometry, and thermal analysis tools essential for pharmaceutical, life sciences, and industrial research. The company holds a dominant position as a premium, high-margin player in the niche analytical instrumentation market, known for its recurring revenue from service and consumables. The current investor narrative is heavily focused on the transformative early-2026 merger with BD's life science and diagnostics business, which is expected to significantly expand Waters' presence in the high-growth diagnostics segment and reshape its growth and margin profile, creating both integration execution risks and long-term synergy opportunities.…
WAT
Waters Corporation
$358.25
Investment Opinion: Should I buy WAT Today?
Rating: Hold. The core thesis is that Waters is a high-quality business in the midst of a risky transformation, with its premium valuation already reflecting much of the success anticipated from the BD merger, leaving asymmetric risk to the downside if execution falters.
Supporting Evidence: The recommendation is grounded in four key data points. First, the valuation is rich at a forward P/E of 21.60x, which is still a premium to many sector peers. Second, while revenue grew 6.83% YoY in Q4, margin compression (net margin down 220 bps YoY) tempers enthusiasm. Third, the stock's severe underperformance (-20.25% relative strength vs. SPY over 1 year) suggests the market is skeptical. Finally, the tight clustering of analyst EPS estimates ($20.98-$21.51) provides a firm near-term earnings floor but offers limited near-term catalyst for upside surprise.
Risks & Conditions: The two biggest risks are merger integration failure and valuation compression from current elevated levels. This Hold rating would upgrade to a Buy if the forward P/E compresses below 18x without a deterioration in the synergy outlook, or if the company demonstrates clear post-merger margin expansion in the next two quarters. It would downgrade to a Sell if revenue growth decelerates below 5% or if the stock breaks below its key $275 support level. Relative to its history and the growth implied by its multiple, the stock is currently fairly valued to slightly overvalued, demanding perfect execution to justify its price.
Sign up to view all
WAT 12-Month Price Forecast
The outlook for WAT is a 'show me' story centered on merger execution. The base case is most likely, with the stock oscillating in a range as the market digests incremental integration updates. The high current valuation limits near-term upside absent flawless execution, while the strong underlying business and cash flow provide material support against a catastrophic bear case. The stance would upgrade to bullish on confirmation of sustained margin improvement post-merger or a valuation drop below 20x forward P/E. It would turn bearish on a breakdown below the $275 support or a significant guidance cut related to integration.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Waters Corporation's 12-month outlook, with a consensus price target around $465.73 and implied upside of +30.0% versus the current price.
Average Target
$465.73
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$287 - $466
Analyst target range
Analyst coverage for Waters is limited, with data indicating only 7 analysts providing estimates, which suggests the stock may have less institutional following than larger-cap peers. The consensus sentiment appears neutral to cautiously optimistic, with recent institutional ratings from firms like Deutsche Bank, Morgan Stanley, and Wells Fargo maintaining 'Hold' or 'Equal Weight' stances, while Guggenheim maintains a 'Buy'. The average estimated EPS for the forward period is $21.27, with a range from $20.98 to $21.51, indicating tight clustering and high conviction in near-term earnings projections. The target price range is not explicitly provided in the data, but the tight range of EPS estimates suggests analysts have a firm grasp on near-term profitability. The lack of a wide dispersion in EPS targets points to lower uncertainty regarding the company's fundamental earnings power in the immediate future. However, the major uncertainty and debate likely revolve around the long-term success of the BD merger integration and the associated synergy realization, which will be the key drivers of the stock's longer-term price targets and multiple. The limited number of covering analysts can lead to higher volatility and less efficient price discovery, especially during transformative events like the current merger.
Bulls vs Bears: WAT Investment Factors
The investment debate for Waters Corporation is a classic tension between a high-quality, cash-generative business with a transformative growth catalyst and the significant execution risks and premium valuation that accompany it. The bear side currently presents stronger evidence in the near term, given the stock's severe underperformance, premium multiples, and the recent margin compression. However, the compelling bull case rests on the potential for the BD merger to successfully reignite growth. The single most important tension is the market's expectation of seamless merger integration and synergy realization (priced into the forward P/E of 21.6x) versus the high historical failure rate of such complex corporate actions. The resolution of this integration over the next 12-18 months will be the primary determinant of shareholder returns.
Bullish
- Strong Recovery Momentum: The stock has shown a significant short-term recovery, with a 3-month price change of +18.88% and a 1-month gain of +6.66%, both outperforming the SPY. This suggests the stock may be bottoming after a severe -31.32% drawdown, with the price rebounding from its 52-week low of $275.05.
- High-Quality, Profitable Business: Waters maintains premium profitability with a Q4 2025 gross margin of 59.79% and an operating margin of 33.31%. Its high return on equity of 25.09% demonstrates efficient capital use, and it generates substantial free cash flow of $539.8 million TTM, providing a solid financial foundation.
- Transformative Merger Upside: The early-2026 merger with BD's life science and diagnostics business is a potential game-changer, expected to expand Waters' market into high-growth diagnostics. This strategic move underpins the market's forward earnings expectations, as seen in the forward P/E of 21.60x versus a trailing P/E of 35.17x.
- Analyst Confidence in Near-Term Earnings: Analyst EPS estimates for the forward period are tightly clustered between $20.98 and $21.51, with an average of $21.27. This high conviction in near-term profitability reduces uncertainty and suggests the core business model remains robust despite merger-related volatility.
Bearish
- Severe Long-Term Underperformance: WAT has significantly underperformed the broader market, with a 1-year price change of +4.74% versus the SPY's +24.99%, resulting in a -20.25% relative strength deficit. The stock is trading at only 57% of its 52-week range ($275.05 to $414.15), indicating persistent negative momentum and investor skepticism.
- Premium Valuation Amidst Execution Risk: Despite recent weakness, the stock trades at a premium to its sector with a trailing P/E of 35.17x and a P/S of 7.14x. This premium valuation leaves little room for error as the company navigates the complex integration of the BD business, creating significant execution risk.
- Margin Compression and Growth Moderation: Year-over-year profitability has slightly eroded, with Q4 2025 net margin at 24.16% compared to 26.51% in Q4 2024. Furthermore, Q4 revenue growth of 6.83% YoY, while positive, represents a deceleration from the strong sequential growth seen earlier in the fiscal year, raising questions about organic momentum.
- High Volatility and Limited Analyst Coverage: With a beta of 1.202, WAT is approximately 20% more volatile than the market, amplifying downside risk during periods of uncertainty. Additionally, limited analyst coverage (only 7 analysts) can lead to less efficient price discovery and higher volatility, especially during the transformative merger period.
WAT Technical Analysis
The stock is in a pronounced downtrend over the past year, with a 1-year price change of only +4.74%, significantly underperforming the SPY's +24.99% gain. As of the latest close of $355.44, the price is trading at approximately 57% of its 52-week range ($275.05 to $414.15), indicating it is much closer to its annual lows than highs, which suggests a potential value opportunity but also reflects persistent negative momentum and investor skepticism. The stock experienced a severe correction in February and March 2026, with the price dropping from around $380 in early February to a low near $283 by mid-March, representing a peak-to-trough decline of over 25% that aligns with the reported max drawdown of -31.32%. Recent momentum shows signs of a tentative recovery from those lows, with a strong 3-month price change of +18.88% and a 1-month gain of +6.66%, both outperforming the broader market's respective gains of +15.14% and +0.74%. This positive short-term divergence from the weak longer-term trend suggests the stock may be attempting to establish a bottom, potentially driven by oversold conditions or initial assessments of the merger's long-term value. However, the recovery remains fragile and within the context of the broader downtrend. Key technical levels are clearly defined, with major support at the 52-week low of $275.05 and formidable resistance at the 52-week high of $414.15. A sustained breakout above the $414 resistance would signal a complete reversal of the bearish trend and renewed institutional confidence, while a breakdown below the $275 support could trigger another leg down. The stock's beta of 1.202 indicates it is approximately 20% more volatile than the market, which is important for risk-adjusted positioning, especially during this period of significant corporate transformation and associated uncertainty.
Beta
1.20
1.20x market volatility
Max Drawdown
-31.3%
Largest decline past year
52-Week Range
$275-$414
Price range past year
Annual Return
+4.6%
Cumulative gain past year
| Period | WAT Return | S&P 500 |
|---|---|---|
| 1m | +4.6% | -0.2% |
| 3m | +18.7% | +14.0% |
| 6m | -6.9% | +7.8% |
| 1y | +4.6% | +25.3% |
| ytd | -6.2% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WAT Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $932.4 million representing a 6.83% year-over-year increase. Examining the sequential quarterly trend from Q1 to Q4 2025 shows revenue progressing from $661.7 million to $932.4 million, indicating healthy sequential growth within the fiscal year. Segment data reveals that the core 'Waters Instrument Systems' and high-margin 'Waters Service' segments are the primary revenue drivers, contributing $354.7 million and $298.9 million respectively in the latest period, underscoring the company's dual-engine model of instrument sales and recurring service revenue. The company is solidly profitable, with Q4 2025 net income of $225.2 million. Profitability metrics are strong, with a gross margin of 59.79% and an operating margin of 33.31% for the quarter, reflecting the premium, high-margin nature of its business. The net margin for the period was 24.16%. While these margins are robust, a comparison to the year-ago Q4 2024 shows a slight compression from a gross margin of 60.07% and a net margin of 26.51%, which may reflect competitive pressures or investment costs ahead of the merger. Balance sheet health is adequate, with a debt-to-equity ratio of 0.58, indicating a moderate level of leverage that is likely manageable. The company generates substantial cash, with trailing twelve-month free cash flow of $539.8 million, providing ample internal resources to fund operations and strategic initiatives like the BD merger integration. The current ratio of 1.73 suggests sufficient short-term liquidity. Return on equity is high at 25.09%, demonstrating efficient use of shareholder capital, though return on assets is a more modest 3.31%, which is typical for an asset-intensive instrumentation business.
Quarterly Revenue
$932362000.0B
2025-12
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.59%
Latest Quarter
Free Cash Flow
$539810000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WAT Overvalued?
Given the consistently positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 35.17x, while the forward PE is significantly lower at 21.60x. This substantial gap implies the market expects a meaningful acceleration in earnings growth, likely driven by the projected synergies and expanded market reach from the BD life sciences merger, effectively pricing in a recovery narrative. Compared to sector averages, Waters trades at a premium. Its trailing PE of 35.17x and forward PE of 21.60x are above typical healthcare equipment and supplies industry averages, which often range in the mid-20s for trailing PE. The Price-to-Sales ratio of 7.14x and EV-to-Sales of 10.75x also suggest a premium valuation. This premium is arguably justified by the company's industry-leading margins, strong competitive moat, and the transformative potential of its recent merger, which could drive superior growth compared to peers. Historically, the current trailing PE of 35.17x sits above the levels seen in recent quarters, such as 25.11x at the end of Q4 2025 and 29.15x at the end of Q3 2025, as per the historical ratios data. This indicates the stock is trading at the higher end of its recent valuation range. This positioning suggests the market has already priced in a significant portion of the expected benefits from the merger, leaving less room for multiple expansion and increasing the stock's sensitivity to execution risks and forward guidance.
PE
35.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 22x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Waters faces risks from slight margin erosion, as evidenced by the year-over-year decline in Q4 net margin from 26.51% to 24.16%. While the debt-to-equity ratio of 0.58 is moderate, the company's premium valuation (P/E 35.17x) creates dependence on sustained high growth to justify its multiple. The core risk is that integration costs from the BD merger further pressure margins before synergies materialize, leading to earnings disappointments against the high forward expectations embedded in the 21.60x forward P/E.
Market & Competitive Risks: The primary market risk is valuation compression. Trading at a trailing P/E of 35.17x and P/S of 7.14x—premiums to sector averages—the stock is vulnerable to de-rating if growth decelerates or merger synergies are delayed. Its beta of 1.202 indicates it is 20% more volatile than the market, amplifying downside during sector rotations or broad market pullbacks. Competitively, the company must successfully integrate BD's diagnostics business to avoid losing market share during the transition period.
Worst-Case Scenario: The worst-case scenario involves a botched merger integration leading to significant customer attrition, synergy delays, and rising costs, culminating in consecutive earnings misses. This could trigger multiple compression towards its historical lows and a re-test of its 52-week low of $275.05. Given the stock's high beta and recent max drawdown of -31.32%, a realistic adverse scenario could see the stock decline by approximately -22% from the current price of ~$355 to the $275 support level, with potential for further downside if the fundamental thesis breaks.
FAQ
The key risks are, in order of severity: 1) Merger Integration Execution Risk: The entire thesis hinges on the successful integration of the BD business; failure would crush the growth narrative. 2) Valuation Compression Risk: Trading at a premium (P/E 35.17x), the stock is vulnerable to de-rating if growth moderates. 3) Operational Risk: Evidence of margin compression exists, with Q4 net margin down 235 bps year-over-year. 4) Market Risk: With a beta of 1.202, the stock will likely fall more than the market in a downturn, as seen in its -31.32% max drawdown.
The 12-month forecast is bifurcated around the success of the BD merger. The base case (60% probability) sees the stock trading between $355 and $390 as integration proceeds without major surprises. The bull case (25% probability) targets a breakout above the 52-week high of $414 towards $450 on stellar synergy results. The bear case (15% probability) warns of a retest of the $275 low if integration fails. The most likely scenario is the base case, predicated on the assumption that the company meets the tight analyst EPS consensus of ~$21.27 without significant margin deterioration.
WAT appears fairly valued to slightly overvalued based on current data. Its trailing P/E of 35.17x and P/S of 7.14x command a clear premium to the healthcare equipment sector. The forward P/E of 21.60x suggests the market is paying for expected earnings growth from the merger. This valuation implies the market expects near-flawless execution and synergy realization. Compared to its own history, trading at the higher end of its recent P/E range, the stock is not cheap. It is priced for success, leaving little margin for error.
WAT is a speculative buy, not a core holding, for investors with a high risk tolerance and a long-term horizon. The potential reward is significant if the BD merger succeeds, as implied by the forward P/E of 21.6x expecting earnings growth. However, the risk is equally high, given the stock's premium valuation, 1.202 beta, and history of severe drawdowns (-31.32%). It could be a good buy for investors who have done deep due diligence on the merger integration plan and are willing to accept volatility, but it is not suitable for conservative portfolios seeking stable returns.
WAT is unequivocally a long-term investment, with a suggested minimum holding period of 3-5 years. The transformative benefits of the BD merger will take multiple years to fully materialize in the financial statements. The stock's high beta (1.202) and history of sharp drawdowns make it unsuitable for short-term trading, as sentiment can swing violently on any merger-related news. Long-term investors can look through this volatility to assess whether the strategic combination creates the durable competitive advantage and growth profile that management envisions.